In a nutshell This study evaluated the effectiveness and safety of pembrolizumab (Keytruda) given after surgery in patients with stage II melanoma. The data showed that pembrolizumab given after surgery for up to 1 year significantly reduced the risk of cancer recurrence or death in these patients. Some background Melanoma is one of the most...
Read MoreTreatment(s) already received-Surgical excision Posts on Medivizor
Long-term outcomes of pembrolizumab therapy for patients with stage III melanoma removed surgically
In a nutshell The aim of this study was to investigate the long-term safety and effectiveness of pembrolizumab (Keytruda) for patients with stage III melanoma that was surgically removed. The study found that patients treated with pembrolizumab were more likely to have an improved outcome. Some background Melanoma is one of the most...
Read MoreEvaluating treatment options after surgery for patients with high-risk melanoma.
In a nutshell The aim of this study was to evaluate different types of therapy after surgery for patients with high-risk melanoma. The study found that add-on targeted therapy or immunotherapy was likely to decrease the risk of disease progression in these patients. Some background Melanoma is a form of skin cancer. Treatment for early-stage...
Read MoreUsing long-term CT and PET/CT scans to identify metastatic recurrence in patients with resected melanoma.
In a nutshell This study evaluated how effective regular scanning is in identifying metastatic recurrence in patients with stage III melanoma that was surgically removed. Results showed that scanning every 6 or 12 months was reasonably good at detecting metastatic recurrence. Some background Melanoma is a form of aggressive skin cancer. Treatment...
Read MoreComparing nivolumab and ipilimumab treatment after surgery for advanced melanoma
In a nutshell This study compared nivolumab (Opdivo) and ipilimumab (Yervoy) for treating advanced melanoma that has been surgically removed. They found that patients treated with nivolumab survived cancer-free for longer than patients treated with ipilimumab. Some background Melanoma which has spread to the lymph nodes or other organs is...
Read MoreCan biological therapies nivolumab and ipilimumab prevent stage IV melanoma from returning?
In a nutshell This study examined if biological therapies nivolumab (Opdivo) and ipilimumab (Yervoy) could safely prevent cancer return in patients with stage IV melanoma that has been surgically removed. The results showed that nivolumab and ipilimumab were effective at preventing recurrence but nivolumab alone was safer for patients. Some...
Read MoreRestaging warranted prior to adjuvant therapy in patients with resected stage IIIB and IIIC melanoma.
In a nutshell This article investigated the need for restaging in patients with stage IIIB and IIIC melanoma before starting adjuvant therapy (AT; treatment after surgery). The authors concluded that restaging should be considered for these high-risk patients before starting the AT. Some background Melanoma a type of skin cancer...
Read MoreFactors influencing survival in patients with stage IV metastatic melanoma
In a nutshell This study looked at factors that were associated with better survival in patients who had surgery for advanced melanoma. The study found that having clear surgical margins, where the cancer has not spread to surrounding tissues, and having a low white blood cell ratio were associated with longer survival. Some background Melanoma...
Read MorePET is effective detecting recurrences in stage 3 melanoma
In a nutshell This study investigated the effectiveness of the imaging method PET (detects active cancer lesions) in detecting relapses after surgery in stage 3 melanoma patients. Researchers suggested that PET allows the detection of most recurrences. Some background Stage 3 melanoma is associated with a high rate of recurrences. Follow-up of...
Read MoreLooking for participants to test the safety and effectiveness of a vaccine combined with TLR agonists to treat melanoma
In a nutshell This phase 1/2 trial aims to test the safety and effectiveness of a combined treatment with the new vaccine LPV7 and TLR agonists in advanced melanoma patients after surgery. The main outcome to be measured will be the treatment toxicity and response of the tumors to the treatment. This trial is recruiting in Houston, Texas and...
Read MoreLooking for advanced melanoma patients to test a vaccine therapy
In a nutshell This phase 2 trial aims to measure the immune system response to a vaccine to treat melanoma. The main outcome of this trial will be to determine the effectiveness of treatment with vaccine therapy in stage 3 or 4 melanoma patients. The details Immunotherapies stimulate the immune system to fight cancer cells the way it would a virus...
Read MoreRelapse of melanoma in head and neck after surgery: effect of radiation therapy
In a nutshell The authors analyzed the patterns of relapse in patients with head and neck melanoma treated with surgery and radiation therapy. Some background Skin melanoma of head and neck is often associated with poor survival. Surgical removal of the affected lymph nodes (tiny, bean-shaped organ that help fight infection) along with the...
Read More